Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It is set to intensify competition with rival Eli Lilly, whose popular ...

At least 40 to 50 students, their hands cuffed with plastic zip-ties, were seen being loaded into New York Police Department vans and buses.

The approval comes at a crucial time, as the patent for semaglutide is set to expire in China in 2026. Novo Nordisk also plans to limit the initial sales of its obesity treatment, Wegovy, in China.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – is the first new medicine to be approved in the US ...